Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
| ▸ | LOXL4 | Q96JB6 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661200 | 0.81 | ESR1 (0.42) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL13390467 | 0.80 | ESR1 (0.38) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL13390396 | 0.80 | RAB9A (0.38) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL13390203 | 0.80 | RAB9A (0.38) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL18116961 | 0.79 | ESR1 (0.41) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL18116997 | 0.79 | ESR1 (0.41) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL18840226 | 0.79 | RAB9A (0.41) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL18116993 | 0.79 | ESR1 (0.41) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL18116995 | 0.79 | ESR1 (0.41) | ESR1PTGS1HSP90AA1MMP3CHRM1 | |
| SCHEMBL13479829 | 0.78 | ALDH1A1 (0.34) | ESR1PTGS1ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180514-B2 | Systems and methods for mechanosynthesis | CBN NANO TECHNOLOGIES INC. (CA) | 2021-11-23 | — | — | US | disclosed |
| US-20210143339-A1 | ORGANIC COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE ORGANIC COMPOUND | LG DISPLAY CO., LTD. (KR) | 2021-05-13 | — | — | US | disclosed |
| EP-3819953-A1 | ORGANIC COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE ORGANIC COMPOUND | LG Display Co., Ltd. (KR) | 2021-05-12 | — | — | EP | disclosed |
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180194783-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170342093-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9828391-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-9529261-B2 | Color-forming composition, color-forming curable composition, lithographic printing plate precursor and plate making method, and color-forming compound | FUJIFILM CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9376454-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150224125-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| US-9040504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8912169-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140194386-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-07-10 | — | — | US | disclosed |
| US-20140171390-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2014-06-19 | — | — | US | disclosed |
| US-7858388-B2 | MS based peptide and protein sequencing via reactions of lysine residues with peroxycarbonate compounds | VANDERBILT UNIVERSITY (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100093883-A1 | Hydroxamic Esters as Photoinitiators | LAMBERTI SPA (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100093883-A1 | Hydroxamic Esters as Photoinitiators | LAMBERTI SPA (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20070249056-A1 | Peptide and Protein Fragmentation by Lysine Residue Originated Reactions | VANDERBILT UNIVERSITY | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342093-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ESR1 1864/4885PTGS1 1665/4885HSP90AA1 2092/4885 |
| US-20070249056-A1 | Peptide and Protein Fragmentation by Lysine Residue Originated Reactions | PTMS, PTMA, PHYKPL | ESR1 3343/4885PTGS1 2737/4885HSP90AA1 1605/4885 |
| US-20180194783-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ESR1 1864/4885PTGS1 1665/4885HSP90AA1 2092/4885 |
| US-20210143339-A1 | ORGANIC COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE ORGANIC COMPOUND | OCIAD1, OCIAD2, ORC3 | ESR1 190/4885PTGS1 3986/4885HSP90AA1 4878/4885 |
| US-10294248-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | ESR1 1864/4885PTGS1 1665/4885HSP90AA1 2092/4885 |
| US-20140194386-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ESR1 1864/4885PTGS1 1665/4885HSP90AA1 2092/4885 |
| US-20140171390-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ESR1 1864/4885PTGS1 1665/4885HSP90AA1 2092/4885 |
| US-20150224125-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ESR1 1864/4885PTGS1 1665/4885HSP90AA1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.